Publications by authors named "A Stasi"

Proline-rich antimicrobial peptides (PrAMPs) have gained attention due to their antimicrobial properties and low cytotoxicity. B7-005, a small optimized PrAMP, exhibits a broader spectrum of activity than native PrAMPs, due to an antimicrobial mechanism based on inhibiting prokaryotic protein synthesis and destabilizing bacterial membranes. However, the toxicity and the efficacy of B7-005 remain poorly understood, so and microbiology and toxicology experiments were used to assess its suitability as an anti-infective agent.

View Article and Find Full Text PDF

The paenilamicins are a group of hybrid nonribosomal peptide-polyketide compounds produced by the honey bee pathogen Paenibacillus larvae that display activity against Gram-positive pathogens, such as Staphylococcus aureus. While paenilamicins have been shown to inhibit protein synthesis, their mechanism of action has remained unclear. Here we determine structures of paenilamicin PamB2-stalled ribosomes, revealing a unique binding site on the small 30S subunit located between the A- and P-site transfer RNAs (tRNAs).

View Article and Find Full Text PDF

Relapse remains a major cause of treatment failure following allogeneic stem cell transplantation (allo-SCT) for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We retrospectively investigated low-dose decitabine and venetoclax (DEC/VEN) as post-transplant maintenance in 26 older patients with AML and MDS. The cumulative incidence of day 100 gIII-IV acute graft versus host disease (GVHD) and 1-year moderate-severe chronic GVHD was 5% and 26%, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • The paenilamicins are hybrid compounds produced by a honey bee pathogen that target Gram-positive bacteria and inhibit protein synthesis.
  • Researchers determined the structure of paenilamicin PamB2 bound to ribosomes, revealing a unique binding site that helps explain how it interacts with the ribosome.
  • The study shows that PamB2 disrupts the movement of mRNA and tRNAs during translation, with its effectiveness influenced by specific modifications on the tRNA, positioning paenilamicins as new translocation inhibitors.
View Article and Find Full Text PDF